The emerging role of new protein scaffold-based agents for treatment of cancer.

Weidle, Ulrich H; Auer, Johannes; Brinkmann, Ulrich; Georges, Guy; Tiefenthaler, Georg

Weidle, Ulrich H; Auer, Johannes; Brinkmann, Ulrich; Georges, Guy; Tiefenthaler, Georg.

Affiliation

Weidle UH; Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Nonnenwald 2, D-82372 Penzberg, Germany. ulrich.weidle@roche.com

Cancer Genomics Proteomics ; 10(4): 155-68, 2013.

Article in En | MEDLINE | ID: mdl-23893924

Subject(s)

Amino Acids/chemistry; Antibodies, Monoclonal/therapeutic use; Neoplasms/drug therapy; Proteins/administration & dosage; Amino Acids/therapeutic use; Antibodies, Monoclonal/chemistry; CTLA-4 Antigen/administration & dosage; CTLA-4 Antigen/chemistry; Humans; Ligands; Neoplasms/genetics; Neoplasms/immunology; Protein Binding; Protein Structure, Secondary; Proteins/chemistry

Key words

Angiogenesis; HER signaling; multivalent; extension of plasma half-life; multispecific; phage and ribosome display; pharmacokinetics; randomisation of loops and ß sheets; review

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Proteins / Amino Acids / Antibodies, Monoclonal / Neoplasms Limits: Humans Language: En Journal: Cancer Genomics Proteomics Journal subject: BIOQUIMICA / GENETICA MEDICA / NEOPLASIAS Year: 2013 Document type: Article Affiliation country: Germany Country of publication: Greece

Search on Google

Add to My VHL

XML

PubMed Links